Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,gmtOffSetMilliseconds,esgPopulated,tradeable,market,exchange,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,priceHint,marketState,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,EXAS,-608852000,171551008,115567000,,-273969000,,-31164000,340989000,298084000,-181662000,-181662000,,-4616000,,,,-242805000,402077000,583739000,103993000,-92307000,,-31164000,-31164000,2073932000,5723977000,3085522000,3648995000,45726000,6734517000,1714000,-2077060000,400995000,2183915000,364000,12345000,1103816000,628914000,314151000,364000,662323000,1775302000,26700000,274151000,257635000,1885033000,89033000,34704000,63797000,-15862000,-317512000,7245000,-2087000,8759000,-387494000,-77227000,43698000,-141000,3232000,-22950000,-1514000,-53727000,-37920000,1146388000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1.4418519,103.32 - 106.4358,104.38,106.26,106.27,8,8,finmb_28311,NasdaqCM,Exact Sciences Corporation,USD,1338962,1413133,-14400000,False,False,us_market,NCM,-4.762,-2.63,-3.07,-34.49023,21.303,105.40806,0.47694397,0.004524739,118.90355,-13.018547,-0.10948829,18164678656,-40.260456,4.970427,15,America/New_York,EDT,105.885,1630511451,1.5050049,104.42,106.4358,103.32,438574,Exact Sciences Corporation,2,REGULAR,0,35.135002,0.4966078,70.75 - 159.54,-53.65499,-0.3363106,70.75,159.54,1620144003,1635165000,1635510600,1.29,,,159.54,70.75,105.41,118.9,1.34M,1.41M,171.55M,,169.99M,0.76%,91.14%,9.41M,5.14,5.53%,5.49%,9.49M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-48.20%,-44.08%,-7.61%,-24.09%,1.55B,9.88,15.60%,1.14B,-513.59M,-745.05M,-4.76,,1.38B,8.03,2.39B,65.50,2.82,21.30,109.08M,-71M,Value,53719,Healthcare,4800,7,2,"Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.",Madison,608 284 5700,WI,5,1609372800,1622505600,6,United States,http://www.exactsciences.com,86400,6,5505 Endeavor Lane,Diagnostics & Research
t-1,EXAS,737391000,171551008,446399000,,-438273000,,-436810000,312278000,366574000,-415302000,-415302000,,-24336000,,,,-1463000,466339000,881641000,99765000,-22971000,,-436810000,-436810000,848426000,4789657000,2101603000,2823489000,40200000,4925092000,1595000,-1968289000,47582000,1237672000,526000,14070000,1491288000,575844000,256783000,526000,597230000,2198594000,29100000,348699000,234785000,1343102000,92265000,35709000,121490000,62773000,-306638000,879859000,4118000,881926000,684625000,111404000,39818000,-137000,-11838000,-26884000,-2067000,458970000,-16570000,1622750000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1.4418519,103.32 - 106.4358,104.38,106.26,106.27,8,8,finmb_28311,NasdaqCM,Exact Sciences Corporation,USD,1338962,1413133,-14400000,False,False,us_market,NCM,-4.762,-2.63,-3.07,-34.49023,21.303,105.40806,0.47694397,0.004524739,118.90355,-13.018547,-0.10948829,18164678656,-40.260456,4.970427,15,America/New_York,EDT,105.885,1630511451,1.5050049,104.42,106.4358,103.32,438574,Exact Sciences Corporation,2,REGULAR,0,35.135002,0.4966078,70.75 - 159.54,-53.65499,-0.3363106,70.75,159.54,1620144003,1635165000,1635510600,1.29,,,159.54,70.75,105.41,118.9,1.34M,1.41M,171.55M,,169.99M,0.76%,91.14%,9.41M,5.14,5.53%,5.49%,9.49M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-48.20%,-44.08%,-7.61%,-24.09%,1.55B,9.88,15.60%,1.14B,-513.59M,-745.05M,-4.76,,1.38B,8.03,2.39B,65.50,2.82,21.30,109.08M,-71M,Value,53719,Healthcare,4800,7,2,"Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.",Madison,608 284 5700,WI,5,1609372800,1622505600,6,United States,http://www.exactsciences.com,86400,6,5505 Endeavor Lane,Diagnostics & Research
t-2,EXAS,227768000,171551008,31471000,,-224394000,,-219884000,252070000,313302000,6331000,6331000,,-23582000,,,,-4510000,408363000,402032000,95061000,-230725000,,-219884000,-219884000,871660000,3865990000,2017270000,2337100000,27761000,4354370000,1505000,-1531479000,49921000,1237672000,1084000,11319000,806678000,252832000,1319000,1084000,603192000,1606627000,23900000,476324000,208206000,1577610000,80427000,26061000,30887000,39979000,16828000,4158000,-9598000,4470000,102761000,81775000,43143000,272000,1788000,-42998000,-312000,248761000,-14327000,1353795000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1.4418519,103.32 - 106.4358,104.38,106.26,106.27,8,8,finmb_28311,NasdaqCM,Exact Sciences Corporation,USD,1338962,1413133,-14400000,False,False,us_market,NCM,-4.762,-2.63,-3.07,-34.49023,21.303,105.40806,0.47694397,0.004524739,118.90355,-13.018547,-0.10948829,18164678656,-40.260456,4.970427,15,America/New_York,EDT,105.885,1630511451,1.5050049,104.42,106.4358,103.32,438574,Exact Sciences Corporation,2,REGULAR,0,35.135002,0.4966078,70.75 - 159.54,-53.65499,-0.3363106,70.75,159.54,1620144003,1635165000,1635510600,1.29,,,159.54,70.75,105.41,118.9,1.34M,1.41M,171.55M,,169.99M,0.76%,91.14%,9.41M,5.14,5.53%,5.49%,9.49M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-48.20%,-44.08%,-7.61%,-24.09%,1.55B,9.88,15.60%,1.14B,-513.59M,-745.05M,-4.76,,1.38B,8.03,2.39B,65.50,2.82,21.30,109.08M,-71M,Value,53719,Healthcare,4800,7,2,"Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.",Madison,608 284 5700,WI,5,1609372800,1622505600,6,United States,http://www.exactsciences.com,86400,6,5505 Endeavor Lane,Diagnostics & Research
t-3,EXAS,168406000,171551008,32673000,,-87009000,,-86142000,225547000,190976000,-90674000,-90674000,,-22912000,,,,-867000,268868000,359542000,77892000,3665000,,-86142000,-86142000,1105115000,3819798000,1956542000,2511193000,40581000,4467735000,1501000,-1311595000,50311000,1237672000,1489000,12102000,703926000,222274000,1319000,1489000,596188000,1504858000,11800000,518731000,165208000,1557327000,82215000,30998000,14423000,-29291000,-6380000,16124000,50070000,16437000,2874000,-6870000,41056000,-186000,-12791000,-24322000,-313000,34465000,-20770000,1282584000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1.4418519,103.32 - 106.4358,104.38,106.26,106.27,8,8,finmb_28311,NasdaqCM,Exact Sciences Corporation,USD,1338962,1413133,-14400000,False,False,us_market,NCM,-4.762,-2.63,-3.07,-34.49023,21.303,105.40806,0.47694397,0.004524739,118.90355,-13.018547,-0.10948829,18164678656,-40.260456,4.970427,15,America/New_York,EDT,105.885,1630511451,1.5050049,104.42,106.4358,103.32,438574,Exact Sciences Corporation,2,REGULAR,0,35.135002,0.4966078,70.75 - 159.54,-53.65499,-0.3363106,70.75,159.54,1620144003,1635165000,1635510600,1.29,,,159.54,70.75,105.41,118.9,1.34M,1.41M,171.55M,,169.99M,0.76%,91.14%,9.41M,5.14,5.53%,5.49%,9.49M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-48.20%,-44.08%,-7.61%,-24.09%,1.55B,9.88,15.60%,1.14B,-513.59M,-745.05M,-4.76,,1.38B,8.03,2.39B,65.50,2.82,21.30,109.08M,-71M,Value,53719,Healthcare,4800,7,2,"Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.",Madison,608 284 5700,WI,5,1609372800,1622505600,6,United States,http://www.exactsciences.com,86400,6,5505 Endeavor Lane,Diagnostics & Research
